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Abstract
There is mounting evidence that pulmonary arterial hypertension (PAH), asthma and chronic obstructive pulmonary
disease (COPD) share important pathological features, including inflammation, smooth muscle contraction and
remodeling. No existing drug provides the combined potential advantages of reducing vascular- and bronchial-
constriction, and anti-inflammation. Vasoactive intestinal peptide (VIP) is widely expressed throughout the
cardiopulmonary system and exerts a variety of biological actions, including potent vascular and airway dilatory
actions, potent anti-inflammatory actions, improving blood circulation to the heart and lung, and modulation of
airway secretions. VIP has emerged as a promising drug candidate for the treatment of cardiopulmonary disorders
such as PAH, asthma, and COPD. Clinical application of VIP has been limited in the past for a number of reasons,
including its short plasma half-life and difficulty in administration routes. The development of long-acting VIP
analogues, in combination with appropriate drug delivery systems, may provide clinically useful agents for the
treatment of PAH, asthma, and COPD. This article reviews the physiological significance of VIP in cardiopulmonary
system and the therapeutic potential of VIP-based agents in the treatment of pulmonary diseases.
1. Introduction
Vasoactive intestinal peptide (VIP) is a 28-amino-acid pep-
tide, which was first isolated from upper intestine, and has
been characterized as a vasodilatory peptide [1]. VIP has a
very widespread distribution in the central and peripheral
nervous systems [2]. It is one of the most abundant neuro-
peptides found in the cardiovascular system and airways
[2-5]. This neuropeptide exerts a wide range of biological
actions, such as positive inotropic and chronotropic effects,
pulmonary and coronary vasodilatation, bronchodilation,
and anti-inflammatory effects, and thus it influences many
aspects of cardiopulmonary function [6-8]. Studies using
VIP deficient animals and using animal models of diseases
have indicated that VIP has significant therapeutic poten-
tial in the treatment of cardiopulmonary diseases, including
pulmonary arterial hypertension (PAH), chronic obstruc-
tive pulmonary disease (COPD) and asthma [9-11].
Clinical manifestation of PAH
PAH is a disabling chronic disorder of the pulmonary
vasculature, which is characterized by abnormal
pulmonary vascular proliferation and remodeling,
vasoconstriction, perivascular inflammation, and throm-
bosis, leading to elevated pulmonary arterial pressure,
increases in peripheral vascular resistance, and it ulti-
mately results in right heart failure and death [12,13].
The past two decades have seen significant advances
with the development and clinical implementation of a
number of medications for the treatment of PAH: pros-
tanoids, endothelin-1 receptor antagonists, and phos-
phodiesterase type 5 inhibitors. However, the results
remain unsatisfactory, with persistent high mortality,
insufficient clinical improvement and no convincing
report of any reversal of the disease process [12,13]. In
addition, the current PAH therapy requires a cocktail of
drugs to manage PAH symptoms and often leads to
drug intolerance [14]. Therefore, it is necessary to
develop additional novel therapeutic approaches that
target the various components of this multifactorial dis-
ease. VIP provides the combined potential advantages of
lowering pulmonary arterial pressure, improving blood
circulation to the heart and lung, reducing inflammation
of the heart and lung tissues, and is readily accepted by
the body because it is natural to it [1-8]. Based on its
multiple biological actions, the development of con-
trolled release airway drug-delivery system with VIP has
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emerged as a novel therapeutic strategy for the treat-
ment of PAH.
Clinical manifestation of COPD and asthma
Chronic inflammatory airway diseases such as bronchial
asthma or COPD are major contributors to the global
burden of disease. COPD is characterized by a chronic,
slowly progressive airway disorder resulting from a com-
bination of pulmonary emphysema and irreversible
reduction in the caliber of the small airways of the lung,
resulting in airflow limitation [15]. Asthma is a complex,
persistent, inflammatory disease characterized by airway
hyperresponsiveness in association with airway inflam-
mation. Although there are many allopathic treatments,
including bronchodilators and corticosteroids, there is
no single medication that is effective against both the
inflammatory and bronchoconstrictive components of
asthma [16]. VIP exerts functions not only as a vasodila-
tor and bronchodilator but also as a potent immunomo-
dulator [1,7,8], thus VIP has significant therapeutic
potential in the treatment of pulmonary diseases, includ-
ing: PAH, asthma and COPD. However, VIP-based
drugs are not yet in clinical use, possibly because the
poor metabolic stability and difficulty in administration
routes. The development of long-acting VIP analogues,
in combination with appropriate drug delivery systems,
may provide clinically useful agents for the treatment of
PAH/asthma/COPD. This article reviews the physiologi-
cal significance of VIP in cardiopulmonary system and
the therapeutic potential of VIP-based agents in the
treatment of pulmonary diseases.
2. Expression and distribution of VIP in
cardiovascular-pulmonary system
VIP is co-localized with acetylcholine in postganglionic
parasympathetic neurons in the cardiovascular and
respiratory systems [17]. In the mammalian heart, VIP
was found in nerve fibers associated with atrial and ven-
tricular myocardium, conduction system, and coronary
vessels [18-21]. Immunofluorescent and radioimmunoas-
say studies have localized VIP to neuronal cell bodies of
the intrinsic cardiac ganglia, axons and dendrites, and
presynaptic nerve terminals from which VIP is released
as a nonadrenergic-noncholinergic neurotransmitter [22].
In the peripheral nervous system, VIP is present in sym-
pathetic ganglia, the vagus nerves, some motor nerves
such as the sciatic nerve, autonomic nerves that supply
exocrine glands, vascular and nonvascular smooth mus-
cle, and ganglion-like clusters of neuronal cell bodies that
provide ‘intrinsic’ organ innervation [18,23].
VIP is abundantly present in normal human lungs
[1,2,24]. VIP-immunoreactivity (IR)-containing cells are
present in the tracheobronchial smooth muscle layer and
glands of airways, and within the walls of pulmonary and
bronchial vessels [25,26]. VIP-IR nerve fibers are found
as branching networks in the respiratory tract [4]. The
frequency of these VIP-ergic fibers decreases as the air-
ways become smaller, and only a few VIP-ergic fibers are
present in bronchioles and alveolar space [26]. The pat-
tern of VIP-ergic nerve fiber distribution largely follows
that of cholinergic nerves, which is consistent with the
colocalization of VIP with acetylcholine [27]. VIP is also
co-localized with nitric oxide synthase (NOS) in human
and guinea-pig airways [28-30]. In human airways, a co-
localized immunoreactivity of VIP and NOS is found in
airway intrinsic neuronal perikarya [28,30]. Furthermore,
VIP has also been identified in some sensory nerves,
including sub-epithelial airway nerves [27,31]; as well as
in immune cells such as mast cells [32], eosinophils
[33,34], and in different mononuclear cells and polymor-
phonuclear leukocytes [35]. A deficiency of VIP in the
respiratory system is considered to be a pathogenetic fac-
tor in pulmonary disease [36,37].
3. VIP release and metabolism
Circulating VIP in men is found in low plasma levels.
However, an increase in plasma concentration has been
detected in conditions, such as gastrointestinal stimula-
tion, during strenuous exercise, acute myocardial infarc-
tion and gastrointestinal tumors [38-41]. Circulating VIP
is produced from VIP-containing nerve fibers. Many
VIP-containing nerves have a perivascular distribution
and it thus seems likely that VIP can exert important
local effects without producing a detectable increase in
systemic levels [42]. Myocardial blood vessels and also
pulmonary blood vessels are innervated by VIP immu-
noreactive nerve fibers, which cause vascular smooth
muscle dilation [18,23]. Endogenous VIP is released by
high frequency nerve stimulation and also is released by
neostigmine, as well as by serotonin, dopaminergic ago-
nists such as bromocriptine and apomorphine, prosta-
glandins (PGE, PGD) and nerve growth factor [43,44].
Under physiological conditions, VIP is mainly cleaved
by endopeptidase, whereas in states of airway inflamma-
tion, mast cell enzymes dominate the degradation of
VIP [45-47]. VIP is readily degraded by enzymes, includ-
ing neutral endopeptidase, mast cell-derived tryptase
and chymase, thus preventing it from relaxing vascular
or tracheal smooth muscle [45-47].
4. VIP receptors in cardiovascular-pulmonary
system
The biological effects of VIP are mediated by two type II
G-protein-coupled receptors: VPAC1 and VPAC2 [48].
Stimulation of VPAC receptors by VIP causes dose-
dependent activation of adenylate cyclase, which
increases cAMP concentrations, and activates cAMP-
and cGMP-dependent protein kinases and leads to
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smooth muscle relaxation via decreasing intracellular
calcium levels [49]. While VIP binds both VPAC1 and
VPAC2 receptors with high affinity, VIP can also bind
with low affinity to the pituitary adenylate cyclase acti-
vating peptide (PACAP) receptor. PACAP is another
secretin family member peptide that exhibits extensive
similarities to VIP and shares VIP receptors and func-
tions [50].
High densities of VIP binding sites were found in the
pulmonary vascular smooth muscle layer and in airway
smooth muscle of large, but not smaller airways. VIP
binding sites are also present in sub-mucosal glands, air-
way epithelium and in alveolar walls [24,51]. In the
human upper respiratory tract, VIP receptors were
found on submucosal glands, epithelial cells, and arterial
but not sinusoidal vessels [5]. VIP receptors are also
expressed in innate immune cell types, including human
mast cells, neutrophils, and peripheral blood monocytes,
and murine macrophages and dendritic cells [52-56].
VIP is thought to play a role in regulating immunity
and inflammation. Studies using VPAC2 receptor
knockout mice and transgenic mice overexpressing the
VPAC2 receptor have revealed that the receptor regu-
lates the balance between T-helper type 1 and 2 lym-
phocytes (Th1 and Th2 cells) by stimulating production
of more Th2-type cytokines, which mediate hypersensi-
tivity reactions (e.g. allergy) [57,58]. Thus, this receptor
is believed to play an important functional role in the
respiratory tract by regulation of immune effects of VIP
in allergic diseases such as allergic bronchial asthma.
The wide spread presence of VIP receptors in a variety
of tissues and organ systems has led to the potential
limitation of its clinical application. Intravenous admin-
istration of VIP has been shown to ameliorate hista-
mine-induced bronchoconstriction in asthmatic subjects;
while it also caused cardiovascular side effects by
decreasing systemic blood pressure, inducing tachycardia
and cutaneous flushing [59]. Thus, the development of
effective drug delivery systems with airway delivery cap-
ability for VIP-based respiratory therapy represents a
possible therapeutic strategy.
5. Role of VIP in heart and blood vessels
VIP is a potent vasodilator in coronary and pulmonary
blood vessels, as well as other systemic blood vessels.
The presence of VIP nerve fibers and their receptors in
the coronary and pulmonary arteries strongly suggests
that this peptide is important in the regulation of cardi-
opulmonary blood flow. VIP induces endothelium-inde-
pendent relaxation in most of the vascular beds,
including cat cerebral artery, dog isolated carotid artery,
pig coronary artery, and bovine pulmonary artery [3-6].
There is direct evidence that VIP acts on heart muscle
in various experimental system. VIP exerts a primary
positive inotropic effect on cardiac muscle. In dogs, VIP
infusion increases cardiac contractility and improves
ventricular-vascular coupling, thus VIP enhances deliv-
ery of mechanical energy from the LV to the circulatory
bed [60]. In isolated atrial or ventricular muscle, VIP,
increases developed isometric force and is greater than
isoproterenol in enhancing ventricular muscle contrac-
tile force [61]. VIP also exerts a primary positive chron-
otropic effect in the heart. Injection of VIP directly into
the dog sinoatrial artery increases heart rate by 37%,
VIP also dose-dependently shortens the atrioventricular
conduction time, decreases the atrial and ventricular
refractory periods [61,62]. Endogenously released VIP
increases atrial and ventricular contractility, and heart
rate. Stimulation of the parasympathetic (vagal) nerves,
during muscarinic and b-adrenergic receptor blockade
in dogs, increases the atrial contractile force by 32%,
increases heart rate by 37%, and also increases right
ventricular contraction and relaxation by 28 and 33%,
respectively [63,64]. In patients with acute myocardial
infarction, the VIP concentration in the plasma may
increase by 33-62% within 6 h of the onset of symptoms
[41]. Upon acute coronary ischemia, VIP is released
from neurons in the coronary vessels and myocardium,
and may also be released from the splanchnic viscera,
and can act as a vasodilator to reduce myocardial ische-
mia [18,65].
6. Biological actions of VIP in airway
VIP is a potent vasodilator of airway smooth muscle in
vitro and in vivo. In isolated tracheal or bronchial seg-
ments, VIP attenuates the constrictor effect of hista-
mine, prostaglandine F2a, endothelin, leukotriene D4,
kallikrein and neurokinin A [66,67]. The bronchodila-
tory effect of VIP in human bronchi is almost 100 times
more potent than adrenergic dilatation by isoproterenol,
and VIP is the most potent endogenous bronchodilator
described so far [68]. VIP is also involved in the regula-
tion of airway mucus secretion. High density VIP-
expressing nerve fibers and VPAC2 mRNA have been
found in airway submucosal glands [25,69]. The role of
VIP in airway mucus secretion has been controversial.
VIP has been shown to have both stimulation and inhi-
bition effects on airway secretion. In the human trachea,
VIP inhibited methacholine-stimulated release of glyco-
proteins and lysozyme [70]. In the upper airways, VIP
was shown to stimulate lactoferrin secretion from
human nasal mucosal cells, but had little effects on
mucous glycoprotein release [71]. VIP inhibits choliner-
gic secretion in ferret trachea, whereas it stimulates cho-
linergic secretion in the cat trachea [72,73]. Therefore,
the importance of VIP in airway mucus secretion
appears to differ from species to markers examined.
Future studies using human tissue and cells need to be
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performed in order to further elucidate the role of VIP
on mucus secretion that associated with hypersecretory
diseases such as COPD or asthma.
7. VIP in inflammatory response
Progressive pulmonary inflammation is the hallmark of
airway diseases, including asthma, COPD and PAH. VIP
has been shown to exert immunomodulating and anti-
inflammatory activities through VIP specific receptors
[74]. VIP inhibits the release of mediators from pulmon-
ary mast cells, interacts with T lymphocytes, prevents
lung injury due to xanthine oxidase and may act as a
free radical scavenger [75-78]. VIP also inhibits the pro-
duction of IL-6, IL-12, TNF alpha, and nitric oxide, and
stimulates IL-10 production, and these effects are mostly
mediated through the constitutively expressed VPAC1
receptor at the transcriptional level via modulation of
NFB and cAMP responsive element (CRE)-binding or
ets-2 complexes [79]. Dunzendorfer et al. have sug-
gested that VIP has an anti-inflammatory effect on eosi-
nophils, reporting that VIP inhibited eosinophil
migration and production of IL-16 in vitro, which subse-
quently inhibited chemotaxis of lymphocytes [80,81].
Delgado et al. also reported that VIP inhibited LPS-
induced inflammatory pathways in monocytes and
macrophages via cAMP-dependent or independent
mechanisms [55]. In addition, it has been suggested that
VIP functions as an important T helper-differentiating
factor that promotes Th2-like and inhibits Th1-like
immune response via several mechanisms, including
preferential survival of Th2 effectors and generation of
memory Th2 cells [82]. In vitro studies show that VIP
treatment leads to the induction of IL-4 and IL-5 in
macrophages, and leads to the inhibition of IFN-gamma
and IL-2 in antigen-primed CD4 T cells [83]. Mice lack-
ing VPAC2 showed increased Th1-type responses which
were characterized by an enhanced delayed type hyper-
sensitivity and a diminished immediate-type hypersensi-
tivity [58] In contrast, T cell over-expression of VPAC2
led to a deviation from the normal CD4 T cell cytokine
expression profile toward a Th2-like profile with ele-
vated blood IgE and IgG1 levels and increased eosino-
phil numbers. These transgenic mice also showed
increased cutaneous allergic reactions, and a decreased
delayed-type hypersensitivity [58]. Future study should
further examine the immune-regulatory role of VIP
using animal models with T cell-related diseases such as
allergic asthma.
8. Therapeutic potential of VIP in PAH
The main pathological features of PAH in the pulmon-
ary vasculature are perivascular inflammation, thrombo-
sis, abnormal growth of vascular smooth muscle cells
and extracellular matrix accumulation, leading to
remodeling of the pulmonary vessel wall, obstruct pul-
monary blood flow and ultimately cause right heart fail-
ure. Current treatment of PAH, which includes the use
of prostacyclins, endothelin receptor antagonists, and
phosphodiesterase type 5 inhibitors, either alone or in
combination, have only limited efficacy in the improve-
ment of clinical symptoms, hemodynamics, and long-
term survival [12-14]. VIP has a large spectrum of biolo-
gical functions including potent dilatory actions in pul-
monary blood vessels and airway smooth muscles,
potent anti-inflammatory actions, inhibition of vascular
smooth muscle cell proliferation, enhancing would heal-
ing, regulation of cell growth and survival, and modula-
tion of airway secretions. Therefore, using VIP-based
drugs to target the various components of this multifac-
torial disease could be a novel therapeutic approach for
the treatment of PAH.
In monocrotaline-induced pulmonary hypertension in
rabbits, VIP dose-dependently decreased pulmonary
artery pressure and pulmonary vascular resistance [83].
Application of VIP to patients with primary pulmonary
hypertension results in substantial improvement of
hemodynamic and prognostic parameters of the disease
without side effects [36]. It decreased the mean pulmon-
ary artery pressure in these patients, increased cardiac
output, and mixed- venous oxygen saturation [36]. Said
indicated that VIP gene is a key modulator of pulmon-
ary vascular remodeling and inflammation [84]. Mice
lacking VIP gene developed moderately severe PAH,
with right ventricular hypertrophy, and thickened pul-
monary artery, as well as perivascular inflammatory cell
infiltrates in the lung [85]. Treatment of the mice with
VIP attenuated both the vascular remodeling and right
ventricular remodeling [85]. Right heart failure is a hall-
mark of severe PAH, and ultimately leading to death. In
animals and in humans, infusion of VIP increases the
epicardial coronary artery cross-sectional area by 27%,
decreases coronary vascular resistance by 46%, and
increases coronary artery blood flow by 200% [20,86].
Application of VIP to patients also increases the left
ventricular fraction shortening by 38% and significantly
increases left ventricular contractility [86,87]. Therefore,
addition to its actions on decreasing pulmonary artery
pressure, VIP also protects the heart.
9. Therapeutic potential of VIP in COPD/asthma
Chronic inflammatory airway diseases such as COPD
and bronchial asthma continue to be an important
cause of morbidity, mortality, and health-care cost
worldwide. The key clinical features of asthma are air-
flow obstruction and airway hyperresponsiveness that
caused by airway inflammation [16]. Many of the
inflammatory events in asthma are thought to be
mediated by Th2 cells. It also involves mast cells,
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eosinophils, neutrophils and mesenchymal cells such as
epithelial cells, fibroblasts, smooth muscle cells and
endothelial cells. The inflammatory mediators, including
cytokines, chemokines, adhesion molecules, proteinases
and growth factors released by these cells participant in
this process at various stages and interact to maintain
and amplify the inflammatory response [11]. Two cate-
gories of drugs are currently used in asthma therapies:
bronchodilators and anti-inflammatory drugs. Despite
the availability of these medications, the asthma epi-
demic continues to increase. The key clinical feature of
COPD is airflow limitation results from airway constric-
tion and irreversible reduction in the caliber of the
small airways of the lung. Cigarette smoking is an
important risk factor of COPD. The airflow limitation
or obstruction that happens in COPD is caused by a
mixture of small airway disease, parenchymal destruc-
tion (emphysema) and in many cases, increased airway
responsiveness (asthma) [15]. Studies have shown that
there is a large overlap of up to 30% between people
who have a clinical diagnosis of COPD and asthma [88].
There is also a high incidence of mild to moderate PAH
prevalence, reaching to 50% in advanced chronic
obstructive COPD [89]. As Said suggested that PAH/
asthma/COPD share important pathological features,
including inflammation, smooth muscle contraction and
remodeling [90]. Inflammation has long been acknowl-
edged as a key feature of the asthma and COPD
[11,15,16,88,89]. Perivascular inflammation has also
been increasingly recognized as a significant component
of clinical and experimental PAH phenotypes [91]. In
these diseases there is increased resistance in, and nar-
rowing of, airways and pulmonary arteries, respectively,
due to airway and pulmonary vasoconstriction, smooth
muscle constriction, and thickening of the walls caused
by smooth muscle and other cell proliferation known as
remodeling [90]. Muscularisation and remodeling of
smaller pulmonary arteries are essential pathological
lesions in PAH [92]. Airway remodeling caused by air-
way inflammation includes an increase in airway wall
thickness, fibrosis, smooth muscle mass and vascularity,
as well as abnormalities in extracellular matrix composi-
tion [89,93]. These shared pathological features suggest
possible common underlying mechanism among PAH/
asthma/COPD.
Mice with targeted deletion of VIP gene, simulta-
neously express airway hyperresponsiveness with airway
inflammation, together with PAH, pulmonary vascular
remodeling and perivascular inflammation. Treatment of
the mice with VIP reversed both sets of phenotypic
changes, confirming that they result from the absence of
the VIP gene [10,84]. Recently, attention has been
drawn to the therapeutic potential of VIP for the clinical
treatment of COPD/asthma on the basis that VIP acts as
a neurotransmitter, the dominant mechanism of human
airway and vascular relaxation, and its anti-inflammatory
properties. Neutrophil accumulation in the airway is a
characteristic feature of COPD and asthma. VIP and its
analogues have been shown to inhibit antigen- or cyto-
kine-induced neutrophil recruitment in the airway in
vivo [94]. VIP has also been shown to attenuate the
cigarette smoke extract-induced apoptotic death of rat
alveolar L2 cells, and protect against human bronchial
epithelial cell damage, enhance airway wound healing
[95,96]. Recent studies show that inhalable powder for-
mulation of VIP derivative, IK312532 attenuates airway
inflammation in ovalbumin challenge-induced asthma/
COPD -like rats and in cigarette smoke-exposed rats
[9,97,98].
10. VIP for clinical use
The key to the therapeutic use of VIP in human disease
is in its delivery. Firstly, VIP is degraded quickly by
enzymes, catalytic antibodies, and spontaneous hydroly-
sis in biological fluids. Secondly, systemic administration
of VIP has been shown to cause cardiovascular side
effects [59]. To overcome the limited clinical effective-
ness of native VIP, VIP incorporated into phospholipids
has been used successfully in animal models of pulmon-
ary hypertension [99]. Furthermore, several peptidase-
resistant VIP-analogues have been developed [100]. VIP
analogue, Ro 25-1553 causes a concentration-dependent
relaxation of airway and pulmonary artery preparations,
with an EC50 of approximately 10 nM and a maximal
relaxation of 70%-75% of the induced tone [101]. In
patients with asthma, inhalation of a selective VPAC2
receptor agonist Ro 25-1553 causes a bronchodilatory
effect. The corresponding maximum bronchodilatory
effect during 24 hours was similar for Ro 25-1553 and
the reference bronchodilator formoterol (beta-2 adreno-
ceptor agonist). However, the bronchodilatory effect of
Ro 25-1553 was attenuated 5 hours after inhalation
whereas formoterol still had a bronchodilatory effect 12
hours after inhalation [102]. Therefore, the development
of effective drug delivery systems for VIP-based respira-
tory therapy remains a significant challenge. It is possi-
ble to envisage that development of controlled-release
biodegradable VIP-based drug system, particularly with
airway delivery capability would have very significant
therapeutic benefits in the treatment of cardiopulmon-
ary diseases, including PAH, COPD and asthma.
11. Conclusion
This article describes the physiological significance of
VIP and its therapeutic potential for the treatment of
cardiopulmonary diseases, including PAH, asthma, and
COPD. VIP exerts a variety of actions, including potent
dilatory actions in pulmonary blood vessels and airway
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smooth muscles, potent anti-inflammatory and anti-pro-
liferative actions, regulation of cell growth and survival,
and modulation of airway secretions. PAH, asthma and
COPD share key mechanisms of pathogenesis, including
inflammation, smooth muscle contraction and remodel-
ing. No other existing or potential drug provides the
combined potential advantages of lowering pulmonary
arterial pressure, reducing bronchoconstriction, improv-
ing blood circulation to the heart and lung, reducing
inflammation of the heart and lung tissues, and enhan-
cing wound healing of bronchial epithelial cells. There-
fore, development of drug delivery system for VIP-based
respiratory therapy may be a promising strategy for the
treatment of PAH, asthma and COPD.
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